CYTOKINETICS, INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.1 EUR | -1.80% |
|
+2.89% | -32.70% |
| 01:30pm | Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants | CI |
| 06-11 | Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 124B | ||||||
| 112B | ||||||
| 22.94B | - | |||||
| 17.02B | - | |||||
| 16.88B |
